CEO Monthly Issue 11 2018

CEO MONTHLY / ISSUE 11 2018 19 Leading the Way in Medical Cannabis Since its inception, Columbia Care has been involved in more than 800,000 successful patient interactions across its dozens of dispensaries. From the outset, the Company has been dedicated to exceeding patient expectations, guaranteeing – to the best of their considerable ability – that the individual needs of the patient are satiated. Nicholas and his team understand that every individual is different and patients are treated with the professionalism that you would expect from any medical establishment. “Our dedicated professionals, many of whom are licensed pharmacists, spend time with each patient to fully understand his or her specific medical needs and recommend the best Columbia Care medicinal format, formulation and dose. Each one of our dispensaries has a dedicated area for patient care where patients can meet privately with pharmacists or other team members to discuss their medical needs.” Nicholas is quick to emphasize the role that Columbia Care’s entire team plays in its enduring success in the industry, as both ambassadors and experts. “The Columbia Care executive team brings decades of experience in finance, healthcare, research and risk management to the company. We have assembled a group with a diverse set of experiences and each person brings expertise that helps the company maintain its status as a leader in the industry. All of our team members, whether behind the scenes or as dedicated professionals on the front lines, are the reason why Columbia Care is able to deliver consistently- dosed, pharmaceutical-quality cannabinoid-based medicines to patients throughout the country.” The conversation soon turns to the unique challenges that Columbia Care, and its peers face operating in the cannabis sector. Chief among them is the almost paradoxical status that cannabis has in the United States, illegal at the federal level, yet seen as safe, warranted and of medicinal benefit in 31 states and U.S. territories. “Cooperation between government officials and medical cannabis operators throughout the country is essential to ensuring that we can continue to help improve patient lives with our products. The classification of cannabis as a Schedule I substance at the federal level has limited large, academic institutions from fully studying both the benefits and risks of medical cannabis in treating a range of clinical conditions in controlled research studies. Notwithstanding, we have worked with the best and brightest minds and their institutions to find work- arounds to this issue. Problems always have a solution, and we have found the solution by engaging and collaborating with the research and medical communities. Expanding on this type of research, as Columbia Care is already doing, will prove extremely important in tackling unmet needs with medical cannabis. Increasing provider comfort with and knowledge about recommending medical cannabis to patients will also be important, and Columbia Care is committed to this mission. As an industry leader, we are well positioned to work hand-in-hand with researchers, government officials and the public to safely increase access of cannabis- based medicines for patients in need.” Finally, in his closing comments, Nicholas spends some time defining Columbia Care’s future as it looks to capitalize on its peerless reputation and presence in the sector. “Columbia Care plans to continue to grow from industry leader in the U.S. to global frontrunner. We plan to continue to work diligently to provide education to multiple audiences, including policy makers, consumers, healthcare workers and researchers.” “Columbia Care is looking forward to continuing to lead the efforts of the medical cannabis industry by consistently innovating, creating intellectual property and commercializing pharmaceutical-quality, cannabinoid-based medicines to address many of the most significant unmet medical needs facing healthcare today.” Company: Columbia Care LLC Website: www.col-care.com Media Contact: Josephine Belluardo, Ph.D. Company: LifeSci Public Relations Website: www.lifescipublicrelations.com